GSE113799
RNA-seq of PC3 prostate cancer cell line xenografts in mice administered the ghrelin receptor antagonist [D-Lys3]-GHRP-6 or PBS for two weeks
The ghrelin receptor antagonist [D-Lys3]-GHRP-6 (or PBS control) was administered for two weeks to NOD/SCID mice with PC3 prostate cancer cell line xenografts. Daily intraperitoneal injections of 20 nmoles/mouse/day [D-Lys3]-GHRP-6 significantly reduced xenograft tumour size at day 9 to 14. RNA-sequencing was performed on xenograft tumours at experimental endpoint (14 days). Overall design: RNA sequencing of PC3 prostate cancer cell line xenografts from NOD/SCID mice. Subcutaneous tumours were allowed to grow until a volume of approximately 100 mm3 was reached, when mice were divided into two experimental groups. Mice then received daily intraperitoneal (i.p.) injections of 20 nmoles/mouse [D-Lys3]-GHRP-6, Sigma-Aldrich, St-Louis, MO, USA) (n=3) or PBS control (n=3) for 14 days.